Kamal Ohson
Memorial University of Newfoundland(CA)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Autoimmune Bullous Skin Diseases, Rheumatoid Arthritis Research and Therapies, Spondyloarthritis Studies and Treatments, Autoimmune and Inflammatory Disorders Research
Most-Cited Works
- → An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist(2009)980 cited
- → A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial(2019)168 cited
- → Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)(2018)88 cited
- → Collagen expression in fibroblasts with a novel LMNA mutation(2006)21 cited
- → Leukocyte adhesion deficiency-I caused by a novel mutation in ITGB2 presenting with pyoderma gangrenosum(2018)5 cited
- → Imiquimod 5% Cream Use for the Treatment of Basal Cell Carcinomas in Elderly Patients, in Long-Term Care Facilities, Not Amenable to Surgical or Radiation Therapy(2006)4 cited
- → OP0219 Early onset of efficacy with apremilast monotherapy in biologic-naÏve patients with active psoriatic arthritis: a phase 3b, randomized, controlled trial(2017)3 cited
- → Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)(2022)
- → AB0943 Sustained improvements with up to 104 weeks of apremilast monotherapy in biologic-naÏve subjects with active psoriatic arthritis: results from a phase 3b, randomised, controlled trial(2018)
- → 34 Mutations in the interleukin-1 receptor antagonist cause a new autoinflammatory disease(2008)